Chemistry and Industry

View more issues:

Articles in Oct 12, 2009 issue of Chemistry and Industry

• The UK Department for Business, Innovation and Skills , through the Technology Strategy Board, is providing 2.5m [pounds sterling] to stimulate innovation by small to medium-sized UK biotech companies through a competition that closes on 19 November 2009
  by Neil Eisberg
• Stick to the science
  by Wolf Hamm
• The quantum classical theory
  by Bob Jones
• Thunder and lightning!
• The chemistry of Christmas
• Bacteria research sought
  by Anthony King
• Nanotubes could beat batteries
  by Andrew Turley
• Safeguarding science: in these days of global research, we need an international solution to the problem of scientific fraud
  by Alex Crawford
• GM plants offer 'green' plastic production
• Manchester unites to benefit industry
  by Tim Chapman
• Vaccine researchers unveil killer strategy; UK researchers believe they could be homing in on the elusive AIDS vaccine
  by Graham Lawton
• Testing for testing's sake
  by Jessica Sandler
• Catalysing business
  by Chris Adams
• Enzyme evolution
  by John Sutherland
• A supercritical success story
  by Martyn Poliakoff
• Doing the solubility splits
  by Eric G. Hope
• Commercial Biosensors: Applications to Clinical, Bioprocess, and Environmental Samples
  by Andrew Scott
• Advanced materials
  by Arno Kraft
• Analytical chemistry
• Out of REACH?
  by Neil Eisberg
• Carbon trading will hurt EU industry competitiveness
  by Patrick Walter
• Lilly acquires ImClone for $6.5bn
  by Neil Eisberg
• Government creates climate department
• EDF snaps up British Energy
• Chaotic pre-registration criticised
  by Neil Eisberg
• Huntsman wins court case
  by Mark Whitfield
• German speciality chemical company Lanxess is restructuring its R&D activities, with completion planned for January 2009
• The first State Of The Nation report from the UK's Cogent Sector Skills Council, Skills for Science Industries: Skills at Work, suggests that the current in-flow of non-graduates into the nation's science sector, through apprenticeships and vocational qua
• GM needs international agreement
  by Patrick Walter
• US algal feedstock specialist PetroAlgae, based in Melbourne, Florida, has been acquired by PetroTech Holdings, a joint venture managed by Valens Capital Management based in Delaware, US, to provide the funding to bring the company's technology to commerc
• UK-based business development company CAMS Group, which specialises in East African energy and food projects, is planning a 240m L/year bioethanol project in Tanzania
• Swiss agribusiness Syngenta is working on the incorporation of the enzyme amylase into the corn kernel itself
• EU says Chinese milk powder poses little risk
  by Muriel Cozier
• Starring role on YouTube
  by Tim Reynolds
• Pharma slips over recent failings
  by Emma Dorey
• The 2008 Ig Nobel prize for chemistry, the irreverent counterpart to the more prestigious Nobel Prize, has gone to two chemists for their conflicting research
• Induced pluripotent stem cells have been hailed as an alternative to embryonic stem cells and a way to avoid the controversy associated with regenerative medicine
• Flexible silicon solar cells that can be fitted to irregular surfaces like fabrics, could find a wide range of energy applications
• Hand-held disease detectors planned
  by Emma Dorey
• Generics' processes under suspicion
  by Emma Dorey
• Mirror, mirror …
• Petchems suffer from oil price hikes: this issue of C&I sees the start of a new regular news feature comparing the performance of the major chemical producers in three key sectors: petrochemicals and polymers, speciality chemicals, and diversified che
  by Ann McRae
• Akzo Nobel
  by Neil Eisberg
• German chemical major BASF has selected OMP Plus supply chain planning software from Belgian supplier OM Partners
  by Neil Eisberg
• SAFC Pharma
  by Neil Eisberg
• Evonik Industries
  by Neil Eisberg
• Arkema
  by Neil Eisberg
• Dutch life sciences and materials company DSM and LibraGen, a bacterial diversity-based process and discovery specialist, have signed an agreement to co-develop omega-transaminases for the production of chiral amines
  by Neil Eisberg
• Nanostructures that respond to stimuli, such as pH, heat and light, are being developed by a consortium of UK universities, including Leeds, Bath and Glasgow Universities, for the regulation of reactions, momentum, and heat and mass transfer inside chemic
  by Neil Eisberg
• Loughborough University has unveiled its Air Products hydrogen refuelling station, the second of its kind in the UK, to refuel hydrogen-powered vehicles used by campus-based organisations
  by Neil Eisberg
• Vertellus Specialties
  by Neil Eisberg
• Olefins specialist LyondellBasell Industries is providing its Lupotech T technology for a 220 000 t/year low density polyethylene plant to be built by Slovnaft Petrochemicals, a subsidiary of the MOL Group, in Bratislava, Slovak Republic, with start-up sc
  by Neil Eisberg
• Global oxo and olefin derivatives supplier Oxea, which has operations in the US and Germany, and phosphorus chemicals producer Chengxing Industrial Group, based in Jianyin, China, are to form a joint venture with Oxea as the majority shareholder
  by Neil Eisberg
• UK-based Ineos Polyolefins, through its Norwegian subsidiary Ineos Bamble, and Puralube Nordic, a joint venture between Germany's Puralube and Norway's Norsk Spesialolje, are to build a 75 000 t/year environmentally friendly lubricant oil production facil
  by Neil Eisberg
• Genzyme
  by Neil Eisberg
• Evonik
  by Neil Eisberg
• The first US interstate carbon trading scheme has begun operations with the auctioning of carbon permits
  by Neil Eisberg
• University of York
  by Neil Eisberg
• Swiss vaccine producer Berna Biotech, an affiliate of Dutch biopharma company Crucell
  by Neil Eisberg
• The US National Science Foundation and Environmental Protection Agency are establishing two Centers for the Environmental implications of Nanotechnology, led by UCLA and Duke University, for the study of how nanomaterials interact with the environment and
  by Neil Eisberg
• Healing hallucinogens: psychoactive drugs are undergoing a renaissance as researchers turn to them to bring relief to patients with difficult-to-treat conditions
  by Arran Frood
• Heptares Therapeutics
• PregLem
• Gerald Coles
• Tessenderlo
• MRC Clinical Science Centre
• Medigene
• Syntaxin
• European Medicines Agency
• Cyclacel Pharmaceuticals
• Association of British Healthcare Industries
• Lectus Therapeutics
• GlaxoSmithKline
• Genentech
• Johnson & Johnson
• Algenol
• Diary
• Partners in discovery: Indian and Western pharma companies are getting together to share the risks and reduce the costs of developing new drugs
  by P. Hari
• Stay on the grass: for something so simple—a combination of grass and earth—turf has proved incredibly difficult to reproduce artificially
  by Jon Evans
• Trial by microdose: preclinical experiments with tiny amounts of drugs in humans often predicts their efficacy better than animal studies
  by Colin Garner

• 1
• 2
• 3
• 4
• 5
• 6
• 7